Seeking Alpha

kastlem

kastlem
Send Message
View as an RSS Feed
View kastlem's Comments BY TICKER:
Latest  |  Highest rated
  • Implant Sciences: Diluted And Deluded [View article]
    Sharvy (aka luvinpeas on yahoo message boards) is an admitted short on this stock. To say he is biased would be gross understatement. His opinion is poisoned for his own profit therefore worthless. Please do not refer to his writing as an article. It is an extended message board bash from a known troll. Sharvy should take care, deliberate manipulation is unlawful.
    Nov 10, 2012. 01:03 AM | 1 Like Like |Link to Comment
  • Implant Sciences: Pumped And Probably Bankrupt [View article]
    Well said!
    Jul 12, 2012. 04:47 AM | Likes Like |Link to Comment
  • Implant Sciences: Pumped And Probably Bankrupt [View article]
    Not in the pinks. Do you understand the pinksheets? This is OTC and we all have no delusions about risk vs reward here. Been at this a good few years myself. As for rolling in cash, again, these are penny stocks! You give a score of examples to support your statement and I could counter with just as many to support my statement. Many a drug or device would not be on the market if no debt and cash flow were a pre-requisite. You are a hyena Sir, a scavenger and your attempt at a Don Quixote disguise is failed.
    Jul 12, 2012. 04:43 AM | 1 Like Like |Link to Comment
  • Implant Sciences: Pumped And Probably Bankrupt [View article]
    Your credibility here as a short is seriously compromised. Been doing this awhile myself. Developmental stage companies don't roll in cash. Potential is the point. Pump and dumps may be old as the hills, but so is bashing by shorts. The more you publish on this the worse it looks. So give it up and go spend the money you just ripped eh?
    Jul 11, 2012. 05:41 PM | 2 Likes Like |Link to Comment
  • Implant Sciences: Pumped And Probably Bankrupt [View article]
    He is short on IMSc. Enough said about his bias.
    Jul 11, 2012. 02:30 PM | Likes Like |Link to Comment
  • Implant Sciences: Pumped And Probably Bankrupt [View article]
    I guessed you were short on this stock from your article title and the timing of publication. Waiting for TSA on this is no different from waiting for FDA on a biotech. You look at the device or drug and gamle on potential. Your piece here is a blatant and obvious attempt to manipulate for personal gain. Perhaps you dont know that is unethical and illegal! The only one who has ripped off the little guys here is you! You, a high school teacher trying to discredit Forbes and GSN, really???
    Jul 11, 2012. 02:23 PM | 1 Like Like |Link to Comment
  • Hana Biosciences: Primed for a Major Comeback [View article]
    Following. Thanks for the article. I also feel HanaBio is an interesting play with positive potential at this time. Additionally for this quarter: Phase 1 study end date (estimated 3/10) for pipeline drug Menadione. BioCEO&Investor Conference Feb 8th 2010. BioEurope International Partnering Conference March 8-10th 2010 Barcelona Spain.
    www.ebdgroup.com/bes/i...
    Feb 7, 2010. 10:32 AM | Likes Like |Link to Comment
  • Soligenix: The Next Cell Therapeutics Comeback Story? [View instapost]
    I was in CTIC from 5 cents until selling the last of my position recently. Pity as Pix is excellent and has a wider market than just 3rd line refractory NHL (trials for 1st line to replace Doxorubicin ongoing, also being trialed for MS and I would expect MG eventually). Opaxio was never a favorite of mine, Brostallicin looks good so far. Management is a major problem there, no secret. As a long time RN specializing in Neonatal ICU I was also in DSCO as their synthetic product Surfaxin is IMPO is superior to bovine preps currently in use. If they can get Aero-Surf to market, it will revolutionize that market for those preemies who do not require long term intubation, reduce BPD/RDS etc. Anyway, point is I got out due to management which turned out to be a correct decision (new CEO now as you probably know, safe to be back in the proverbial water since that change:-). Clearly even with a great pipeline management can make or break a company. Can you shed any light on how effective management at SNGX is?
    Oct 2, 2009. 02:13 AM | Likes Like |Link to Comment
  • Soligenix: The Next Cell Therapeutics Comeback Story? [View instapost]
    Just wanted to add: Do not take my above comment above wrongly! I would not have bothered with it if I did not see real potential for Joseph to become a highly valued blogger in biotech. I apologize to Joseph for putting the critique here (and yes, I didn't have my glasses on and made a few typos above LOL! ). Now I am following, I look forward to seeing more from him, and will refrain from offering further such criticisms in this forum.
    Oct 1, 2009. 12:23 PM | Likes Like |Link to Comment
  • Soligenix: The Next Cell Therapeutics Comeback Story? [View instapost]
    Joseph.. You compiled a very good analysis and are well qualified to comment per your bio. However you got bogged down in over-using the comparison with CTIC as your device of presentation. Your readers want to know about stock A, but read far more than they would want or need to about stock B. You lost focus, and you risked losing your reader's attention as the vehicle you used took over the piece. This is turn produced an overall negativite voice, when your purpose was to be positive about SNGX.
    Better not say in a thousand words what you can say in ten. When you edit your work remember the following points: 1. Keep focus where you want it, not on your device. 2. Most investors are scanning a large number of stocks and do not have time for an over-long essay (attention span of intelligent hamsters basically). 3. Revise Revise Revise - red pen anything that does not move your point forward.
    Small point: SNGX was formerly (not formally) known as DOR.
    Don't worry luv, everyone's a critic!! I have decided to follow you just edit more effeiciently:-) kastlem.
    Oct 1, 2009. 11:47 AM | Likes Like |Link to Comment
  • ASCO: Whose Presentations Look the Most Promising? [View article]
    Erbitux and Vectibix Grade 3 & 4 acneform rashes, and hypomagnemia are significant in their safety profiles. I feel Nimotuzumab (95% humanized monoclonal EGFR targeting anti-body which trialed against these two) is interesting as these side effects were reduced to <1%. YMI may be small but with a remarkable safety profile in comparision, it could give the big pharma a run for its money. We shall see. Nimo also is best used in patients with normal KRAS gene. It is worth noting radiotherapy increases EGFR expression.
    Jul 8, 2009. 01:20 AM | 1 Like Like |Link to Comment
COMMENTS STATS
11 Comments
6 Likes